The University of Southampton
University of Southampton Institutional Repository

The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer

The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
Thromboembolism is a well recognised complication of systemic chemotherapy and cancer. Its incidence
is frequently not reported in clinical trials of adjuvant chemotherapy for early stage breast cancer. Our
own experience suggested that thromboembolic complications were common and we undertook a retrospective review of consecutive patients receiving adjuvant chemotherapy to determine the incidence and morbidity/mortality of this complication. A total of 280 consecutive patients were identified who had received adjuvant ECMF chemotherapy
between January 2001 and February 2007. Thromboembolic events occurred in 21 patients (7.5%). Events
were distributed across chemotherapy cycles, but were more common during CMF chemotherapy (18 cases vs 3 cases). Patients over the age of 60 years appeared to be at particular risk of thromboembolism with an event rate of 27% (15/56 patients). Thromboembolic events were associated with dose delays and cessation of chemotherapy in some patients. With a median follow up of 28 months there is no
significant difference in the incidence of breast cancer recurrence (16.7% vs 14.3%, p ¼ 0.9) or overall
survival (89.5% vs 89.9%, p ¼ 0.8) between patients who experienced a thromboembolic event during
adjuvant chemotherapy and those who did not. Based on the incidence of thromboembolism in our unselected patient population we believe that further prospective studies are indicated seeking to identify those patients at increased risk of this important complication who might benefit from
thromboprophylaxis.
thromboembolism, breast cancer, chemotherapy
0960-9776
151-154
Nolan, Luke
76616eba-b3a6-4d74-ad1b-db49dd8ebc01
Darby, Angela
e56070b0-f2a4-4b7d-b50b-42e22a24aa23
Boleti, Katia
2297f04a-6a9d-4d70-a9e1-7b2d6599c985
Simmonds, Peter
27d4c068-e352-4cbf-9899-771893788ade
Nolan, Luke
76616eba-b3a6-4d74-ad1b-db49dd8ebc01
Darby, Angela
e56070b0-f2a4-4b7d-b50b-42e22a24aa23
Boleti, Katia
2297f04a-6a9d-4d70-a9e1-7b2d6599c985
Simmonds, Peter
27d4c068-e352-4cbf-9899-771893788ade

Nolan, Luke, Darby, Angela, Boleti, Katia and Simmonds, Peter (2011) The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. The Breast, 20 (2), 151-154. (doi:10.1016/j.breast.2010.09.001). (PMID:20970333)

Record type: Article

Abstract

Thromboembolism is a well recognised complication of systemic chemotherapy and cancer. Its incidence
is frequently not reported in clinical trials of adjuvant chemotherapy for early stage breast cancer. Our
own experience suggested that thromboembolic complications were common and we undertook a retrospective review of consecutive patients receiving adjuvant chemotherapy to determine the incidence and morbidity/mortality of this complication. A total of 280 consecutive patients were identified who had received adjuvant ECMF chemotherapy
between January 2001 and February 2007. Thromboembolic events occurred in 21 patients (7.5%). Events
were distributed across chemotherapy cycles, but were more common during CMF chemotherapy (18 cases vs 3 cases). Patients over the age of 60 years appeared to be at particular risk of thromboembolism with an event rate of 27% (15/56 patients). Thromboembolic events were associated with dose delays and cessation of chemotherapy in some patients. With a median follow up of 28 months there is no
significant difference in the incidence of breast cancer recurrence (16.7% vs 14.3%, p ¼ 0.9) or overall
survival (89.5% vs 89.9%, p ¼ 0.8) between patients who experienced a thromboembolic event during
adjuvant chemotherapy and those who did not. Based on the incidence of thromboembolism in our unselected patient population we believe that further prospective studies are indicated seeking to identify those patients at increased risk of this important complication who might benefit from
thromboprophylaxis.

This record has no associated files available for download.

More information

Published date: 2011
Keywords: thromboembolism, breast cancer, chemotherapy

Identifiers

Local EPrints ID: 181389
URI: http://eprints.soton.ac.uk/id/eprint/181389
ISSN: 0960-9776
PURE UUID: 80fa477f-36b1-4c1c-8e41-29af196be89c

Catalogue record

Date deposited: 14 Apr 2011 10:47
Last modified: 14 Mar 2024 02:55

Export record

Altmetrics

Contributors

Author: Luke Nolan
Author: Angela Darby
Author: Katia Boleti
Author: Peter Simmonds

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×